How far can institutional capital shape digital health innovation?

Scale increasingly depends less on venture capital backing.

The Asia-Pacific region’s digital health market is consolidating as institutional capital overtakes venture funding, limiting early-stage startup pathways to scale.

Its digital health funding reached $2.65b in deals in the first quarter, whilst venture capital totalled $244m, Galen Growth Asia Pte. Ltd. said in an April report.

It said the gap signals a structural shift away from startup-led expansion toward institution-led adoption. It added that scale increasingly depends on governments, corporations, and healthcare providers rather than venture capital backing.

Galen Growth said 228 corporate-venture partnerships were recorded in the quarter, showing that collaboration is becoming a primary route to scale alongside financing.

Smart Health Asia, in a December 2025 report, said the region’s healthcare market was $2.4b in 2025 and is projected to hit $5t by 2030, representing about 40% of global healthcare growth.

Capital is also concentrated in specific subsectors. Galen Growth said funding is flowing into medical imaging, health insurance, healthcare operations and omics research, rather than consumer health applications.

Smart Health Asia said artificial intelligence-driven ventures captured 63% of Asia-Pacific digital health funding in the first half of 2025. Startups focused on remote monitoring devices attracted $120m, up 10% year on year.

Despite strong investment activity, Galen Growth said most health systems remain in early stages of integrated digital care. It cited regulatory fragmentation, data sovereignty concerns, and uneven connectivity as barriers to cross-border deployment.

The report also highlighted a nine-to-one ratio of partnerships to pure venture deals, reflecting a system-led adoption model across the region.

Questions to ponder

1. Can startups scale without institutional partners?
2. Is digital health growth becoming partnership-led rather than venture-led?
3. How will regulatory fragmentation affect cross-border healthcare deployment?